Informations générales (source: ClinicalTrials.gov)
French Cohort on the Becoming of Recent Articular Psoriatic Rheumatism (A Psoriatic Arthritis CoHort)
Observational
Assistance Publique - Hôpitaux de Paris (Voir sur ClinicalTrials)
février 2020
mars 2034
12 septembre 2025
Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease, belonging to the
wide spectrum of spondyloarthritis, but with the particularity to be associated with
personal psoriasis or familial psoriasis. PsA can be a very disabling disease through
progressive and irreversible joint damage. Long-term functional prognosis of patients
with PsA is correlated with the presence and severity of the radiographic joint lesions
of the disease.
However, the proportion of patients who will develop those peripheral joint damages is
not yet known and less over the factors which are associated/involved in such an
aggressive pattern of the disease. Early identification of this subgroup of patients is
particularly important for determining early "intensive" treatment, strict management
with a Treat To Target approach, and identification of new treatments with a stronger
structural effect.
The main objective of this prospective 10 years cohort is to describe the 5 years
structural (radiographic) severity of recent PsA with recent peripheral arthritis.Some of
the secondary objectives are to describe the 10 years structural severity within those
patients, and to determine the predictive factors of those 5 and 10 years radiographic
lesions (genetic, environmental, clinic, therapeutic factors).
APACHE will provide a unique longitudinal standardized database concerning patients with
PsA with very recent peripheral arthritis. Research projects which will based on those
collected data should allow to identify the mechanisms of aggressive joint damage, to
highlight mew treatments targets, to better describe the burden of the disease, to test
previous or develop new assessments tolls, to develop early diagnostic criteria
Etablissements
Critères
Tous
Inclusion Criteria:
- Women or men aged from 18 to 60 inclusive
- First episode of peripheral arthritis in the last 12 months, authenticated by a
rheumatologist
- Psoriasis diagnosed by a practitioner or family history of psoriatic arthritis
(first-degree relative [parent or sibling] or second degree relative)
- Arthritis most likely recognized as a psoriatic arthritis by a rheumatologist
(diagnostic confidence score : ≥ 7 out of 10)
- Signed informed consent form
- Affiliation to a social security system
- Women or men aged from 18 to 60 inclusive
- First episode of peripheral arthritis in the last 12 months, authenticated by a
rheumatologist
- Psoriasis diagnosed by a practitioner or family history of psoriatic arthritis
(first-degree relative [parent or sibling] or second degree relative)
- Arthritis most likely recognized as a psoriatic arthritis by a rheumatologist
(diagnostic confidence score : ≥ 7 out of 10)
- Signed informed consent form
- Affiliation to a social security system
- Formal diagnostic of inflammatory rheumatism other than psoriatic arthritis
- Treatment or history of treatment with a biomedicine
- Patient receiving csDMARDS or apremilast treatment for 1 year or more
- Patient having received csDMARDS or apremilast treatment during the last 12 months
- Oral steroids in the last 4 weeks, above 10 mg/d of prednisone or with modified
dosage
- intravenous or intra articular steroids in the last 4 weeks
- IRM contraindication
- Cognitive, mental or psychic disorders impeding protocol accomplishment
- Difficulties with French language understanding
- Patient under tutorship or curatorship
- Pregnancy